Swiss stocks – Factors to watch on Feb 24

ZURICH, Feb 24 (BestGrowthStock) – Swiss stocks are poised to open
higher on Wednesday, mirroring broadly stronger European
bourses.

The Swiss blue-chip index SMI(.SSMI: ) was indicated to open
33 points higher at 6,682 points, premarket data provided by
bank Clariden Leu showed.(CLPRE: )

The following are some of the main factors expected to
affect Swiss stocks on Wednesday:

ROCHE (ROG.VX: )

* The European Medicines Agency granted a positive opinion
for Xeloda in combination with oxaliplatin for the adjuvant
treatment of early colon cancer.

* The U.S. Food and Drug Administration said on Tuesday that
HIV drugs Invirase, made by Roche’s Genentech unit, and Norvir
might lead to an abnormal heart rhythm when used in combination,
according to preliminary data the agency was reviewing.

For related news, click on [ROGN.VX]

COMPANY STATEMENTS [CNR-CH]

* Basilea (BSLN.S: ) announces global partnership with
Astellas for its antifungal isavuconazole. [BSLN.S]

* Ypsomed (YPSN.S: ) is adapting the structure for the manual
assembly of pens and production-related support functions due to
changes in the product mix. [YPSN.S]

ECONOMY [M-CH]

EQUITY RESEARCH [CH-RCH]

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

(.EX.S: ) for all Swiss stocks

(.EXSMI.S: ) for blue chips

(.EXNSMI.S: ) for other stocks

Investment Advice

Swiss stocks – Factors to watch on Feb 24